[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor

• Published in: British journal of pharmacology 2002-05, Vol.136 (2), p.303-311
• Main Authors: Calo, Girolamo, Rizzi, Anna, Rizzi, Daniela, Bigoni, Raffaella, Guerrini, Remo, Marzola, Giuliano, Marti, Matteo, McDonald, John, Morari, Michele, Lambert, David G, Salvadori, Severo, Regoli, Domenico
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Cell receptors; Cell structures and functions; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Fundamental and applied biological sciences. Psychology; Guinea Pigs; In Vitro Techniques; isolated tissues; locomotor activity, mice; Male; Medical sciences; Mice; Molecular and cellular biology; Motor Activity - drug effects; Motor Activity - physiology; Narcotic Antagonists; native and recombinant receptors; Neuropeptide receptors; Neuropharmacology; Neurotransmitters. Neurotransmission. Receptors; Nociceptin/orphanin FQ; NOP receptors; Opioid Peptides - chemistry; Opioid Peptides - metabolism; Opioid Peptides - pharmacology; Pain Measurement - drug effects; Peptide Fragments - chemistry; Peptide Fragments - metabolism; Peptide Fragments - pharmacology; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems; Pharmacology. Drug treatments; Rabbits; rat cerebral cortex synaptosomes; Rats; Rats, Sprague-Dawley; receptor antagonist; Receptors, Opioid - metabolism; tail withdrawal assay; UFP‐101
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1038/sj.bjp.0704706

Nociceptin/orphanin FQ (N/OFQ) modulates several biological functions by activating a specific G‐protein coupled receptor (NOP). Few molecules are available that selectively activate or block the NOP receptor. Here we describe the in vitro and in vivo pharmacological profile of a novel NOP receptor ligand, [Nphe1,Arg14,Lys15]N/OFQ‐NH2 (UFP‐101). UFP‐101 binds to the human recombinant NOP receptor expressed in Chinese hamster ovary (CHO) cells with high affinity (pKi 10.2) and shows more than 3000 fold selectivity over classical opioid receptors. UFP‐101 competitively antagonizes the effects of N/OFQ on GTPγ35S binding in CHOhNOP cell membranes (pA2 9.1) and on cyclic AMP accumulation in CHOhNOP cells (pA2 7.1), being per se inactive at concentrations up to 10 μM. In isolated peripheral tissues of mice, rats and guinea‐pigs, and in rat cerebral cortex synaptosomes preloaded with [3H]‐5‐HT, UFP‐101 competitively antagonized the effects of N/OFQ with pA2 values in the range of 7.3–7.7. In the same preparations, the peptide was inactive alone and did not modify the effects of classical opioid receptor agonists. UFP‐101 is also active in vivo where it prevented the depressant action on locomotor activity and the pronociceptive effect induced by 1 nmol N/OFQ i.c.v. in the mouse. In the tail withdrawal assay, UFP‐101 at 10 nmol produces per se a robust and long lasting antinociceptive effect. UFP‐101 is a novel, potent and selective NOP receptor antagonist which appears to be a useful tool for future investigations of the N/OFQ‐NOP receptor system. British Journal of Pharmacology (2002) 136, 303–311; doi:10.1038/sj.bjp.0704706